Patents by Inventor Jack Ladenson

Jack Ladenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Miox antibody and assay
    Patent number: 10060925
    Abstract: The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 28, 2018
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Joseph P. Gaut, Jack Ladenson, Dan Crimmins, Vijay Modur
  • Markers for brain damage
    Patent number: 9982299
    Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: May 29, 2018
    Assignee: Washington University
    Inventors: Jack Ladenson, Yvonne Landt, Vijay Modur, Omar Laterza
  • MIOX ANTIBODY AND ASSAY
    Publication number: 20160216264
    Abstract: The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.
    Type: Application
    Filed: July 11, 2014
    Publication date: July 28, 2016
    Inventors: Joseph P. Gaut, Jack Ladenson, Dan Crimmins, Vijay Modur
  • MARKERS FOR BRAIN DAMAGE
    Publication number: 20120021534
    Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.
    Type: Application
    Filed: July 20, 2011
    Publication date: January 26, 2012
    Applicant: Washington University
    Inventors: Jack LADENSON, Yvonne Landt, Vijay Modur, Omar Laterza
  • Markers for brain damage
    Patent number: 7985555
    Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: July 26, 2011
    Assignee: Washington University
    Inventors: Jack Ladenson, Yvonne Landt, Vijay Modur, Omar Laterza
  • Methods for determining and lowering caffeine concentration in fluids
    Patent number: 7615218
    Abstract: Single-chain, camelized heavy chain antibodies immunospecific for caffeine and stable at high temperatures are useful for analysis and recovery of caffeine in or from fluids. A device that provides a single-step lateral flow assay for caffeine and a useful peptide spacer are also described.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: November 10, 2009
    Assignee: Washington University
    Inventors: Jack Ladenson, Ruth Ladenson, Yvonne Landt, Dan Crimmins
  • Markers For Brain Damage
    Publication number: 20080131881
    Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.
    Type: Application
    Filed: June 27, 2005
    Publication date: June 5, 2008
    Inventors: Jack Ladenson, Yvonne Landt, Vijay Modur, Omar Laterza
  • Methods for determining and lowering caffeine concentration in fluids
    Publication number: 20070178524
    Abstract: Single-chain, camelized heavy chain antibodies immunospecific for caffeine and stable at high temperatures are useful for analysis and recovery of caffeine in or from fluids. A device that provides a single-step lateral flow assay for caffeine and a useful peptide spacer are also described.
    Type: Application
    Filed: September 21, 2005
    Publication date: August 2, 2007
    Inventors: Jack Ladenson, Ruth Ladenson, Yvonne Landt, Dan Crimmins
  • Method of assessing the risk of atherosclerosis
    Publication number: 20050266497
    Abstract: A method for aiding in the determination of whether a living or deceased human is afflicted with or will likely have atherosclerosis respectfully, the method comprising determining the level of SPRR3 protein in a intimae or body fluid sample by using molecular localization analysis technique comparing the determined level of SPRR3 protein in the biological sample obtained from said individual with a range of SPRR3 levels previously defined as characteristic for humans having atherosclerosis, concluding from the comparison that the person is likely suffering from atherosclerosis when a SPRR3 level is in the range previously defined as characteristic for the presence of atherosclerosis as an indication that the individual is suffering from or has suffered from atherosclerosis.
    Type: Application
    Filed: May 2, 2005
    Publication date: December 1, 2005
    Inventors: Jack Ladenson, Pampee Young, Vijay Modur